 The present study investigates the potential of a new therapeutic approach in lupus nephritis combining rituximab anti-CD20 and belimumab anti-BAFF. The main goal of the study is to assess the reduction and seroconversion of pathogenic autoantibodies, to evaluate clinical improvement and assess the safety and feasibility of long-term B-cell depletion. 